RT Journal Article SR Electronic T1 18F-FDG PET/CT Identifies Predictors of Survival in Patients with Locally Advanced Cervical Carcinoma and Paraaortic Lymph Node Involvement to Allow Intensification of Treatment JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1442 OP 1447 DO 10.2967/jnumed.119.238824 VO 61 IS 10 A1 Hélène Leray A1 Erwan Gabiache A1 Frédéric Courbon A1 Isabelle Brenot-Rossi A1 Hélène Colineaux A1 Benoît Lepage A1 Eric Lambaudie A1 Alejandra Martinez A1 Marie Voglimacci A1 Ariane Weyl A1 Marion Deslandres A1 Anne Ducassou A1 Stéphanie Motton A1 Charlotte Vaysse A1 Elodie Chantalat YR 2020 UL http://jnm.snmjournals.org/content/61/10/1442.abstract AB Our objective was to use 18F-FDG PET/CT to identify a high-risk subgroup requiring therapeutic intensification among patients with locally advanced cervical cancer (LACC) and paraaortic lymph node (PALN) involvement. Methods: In this retrospective multicentric study, patients with LACC and PALN involvement concurrently treated with chemoradiotherapy and extended-field radiotherapy between 2006 and 2016 were included. A senior nuclear medicine specialist in PET for gynecologic oncology reviewed all 18F-FDG PET/CT scans. Metabolic parameters including SUVmax, metabolic tumor volume, and total lesion glycolysis (TLG) were determined for the primary tumor, pelvic lymph nodes, and PALNs. Associations between these parameters and overall survival (OS) were assessed with the Cox proportional hazards model. Results: Sixty-eight patients were enrolled in the study. Three-year OS was 55.5% (95% confidence interval, 40.8–68.0). When adjusted for age, stage, and histology, pelvic lymph node TLG, PALN TLG, and PALN SUVmax were significantly associated with OS (P < 0.005). Conclusion: 18F-FDG PET/CT was able to identify predictors of survival in the homogeneous subgroup of patients with LACC and PALN involvement, thus allowing therapeutic intensification to be proposed.